Trial Profile
A Phase 1B Study of PTC596 in Combination With Dacarbazine in Patients With Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Dacarbazine (Primary) ; Unesbulin (Primary)
- Indications Leiomyosarcoma
- Focus Adverse reactions
- Sponsors PTC Therapeutics
- 24 Oct 2023 Results assessing drug-drug interactions (DDI) and the impact of food on the PK of unesbulin , presented at the 48th European Society for Medical Oncology Congress.
- 28 Jul 2023 Planned End Date changed from 31 Jul 2023 to 31 Jan 2024.
- 28 Jul 2023 Planned primary completion date changed from 31 Jul 2023 to 31 Jan 2024.